Comprised of former buy- and sell-side professionals, Westwicke’s managing directors can attest to how notoriously difficult financial markets are to predict. One area where there is at least some degree of certainty is the heightened challenge of executing a financing in the midst of an election year, where initial public offering (IPO) activity and appetite for risk tend to diminish, particularly in a politically-charged vertical such as healthcare.
Posts by Constantine Davides
Constantine Davides is a Managing Director on Westwicke's life sciences, healthcare services, and healthcare technology teams. He has extensive sell-side, buy-side, and industry experience. He has a BA from Wesleyan University and an MBA from Carnegie Mellon.
Posted on June 27th, 2018. Posted by Constantine Davides
We are regularly asked to characterize the market backdrop for potential life sciences IPOs. While biotech ETF performance can offer a glimpse at current conditions, we dug deeper and analyzed recent biopharma index strength, IPO activity and follow-on offerings, among other metrics.
Our analysis indicates the market remains strong, albeit with some signs of moderation.
Clinical trial data disclosure can be tricky.
Download our checklist of 10 disclosure guidelines to minimize risk and maximize the impact of good news.